Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruboxistaurin for diabetic clinically significant macular edema assessed by OCT
2005-000900-15Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic macular edema (DME) comparing Ruboxistaurin with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started May 2005; status: completed.
02
Drugs
ruboxistaurin
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2005-000900-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000900-15.